Literature DB >> 12351518

What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome.

Roy Homburg1.   

Abstract

The criteria for diagnosis and definition of polycystic ovarian syndrome used by clinicians and investigators are almost as heterogeneous as the syndrome itself. This has confused and seriously hindered the clarification of the genetics, aetiology, clinical associations and assessment of treatment and later sequelae of the syndrome. This article proposes a consensus for a unifying balanced and practical working definition for use as a standard. The proposal incorporates confirmation of the diagnosis suggested by clinical symptoms by ultrasound, and the use of hormonal estimations if typical ultrasound features are not seen and for the purpose of defining subsets of the syndrome. This consensus proposal attempts to bridge the gap between predominately American biochemical marker-based diagnosis and predominately European reliance on ultrasound as a sine qua non for diagnosis. It has been deliberately designed to be simple, practical and cheap, and if universally adopted as a standard could contribute much to all future work involving this most prevalent of syndromes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351518     DOI: 10.1093/humrep/17.10.2495

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  17 in total

1.  Interventional studies for polycystic ovarian syndrome in children and adolescents.

Authors:  Patricia Myriam Vuguin
Journal:  Ped Health       Date:  2010-02

2.  No association between the microsatellite polymorphism (TTTTA)n in the promoter of the CYP11A gene and ovarian hyperstimulation syndrome.

Authors:  Polonca Ferk; Ksenija Gersak; Natasa Teran
Journal:  J Assist Reprod Genet       Date:  2006-01-04       Impact factor: 3.412

Review 3.  Polycystic ovarian syndrome: diagnosis and management.

Authors:  Michael T Sheehan
Journal:  Clin Med Res       Date:  2004-02

4.  Cholesterol, endocrine and metabolic disturbances in sporadic anovulatory women with regular menstruation.

Authors:  Sunni L Mumford; Enrique F Schisterman; Anna Maria Siega-Riz; Audrey J Gaskins; Anne Z Steiner; Julie L Daniels; Andrew F Olshan; Mary L Hediger; Kathleen Hovey; Jean Wactawski-Wende; Maurizio Trevisan; Michael S Bloom
Journal:  Hum Reprod       Date:  2010-11-28       Impact factor: 6.918

5.  Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.

Authors:  Etelka Moll; Patrick M M Bossuyt; Johanna C Korevaar; Cornelis B Lambalk; Fulco van der Veen
Journal:  BMJ       Date:  2006-06-12

6.  Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial.

Authors:  Neriman Bayram; Madelon van Wely; Eugenie M Kaaijk; Patrick M M Bossuyt; Fulco van der Veen
Journal:  BMJ       Date:  2004-01-24

7.  Novel PGK1 determines SKP2-dependent AR stability and reprograms granular cell glucose metabolism facilitating ovulation dysfunction.

Authors:  Xia Liu; Changfa Sun; Kexin Zou; Cheng Li; Xiaojun Chen; Hangchao Gu; Zhiyang Zhou; Zuwei Yang; Yaoyao Tu; Ningxin Qin; Yiran Zhao; Yimei Wu; Yicong Meng; Guolian Ding; Xinmei Liu; Jianzhong Sheng; Chuanjin Yu; Hefeng Huang
Journal:  EBioMedicine       Date:  2020-10-21       Impact factor: 8.143

8.  The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.

Authors:  M Yilmaz; A Biri; A Karakoç; F Törüner; B Bingöl; N Cakir; B Tiras; G Ayvaz; M Arslan
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

9.  The pathogenetic enigma of polycystic ovary syndrome.

Authors:  S Speca; C Napolitano; G Tagliaferri
Journal:  J Ultrasound       Date:  2007-10-22

10.  Calpain 10 gene single-nucleotide 44 polymorphism may have an influence on clinical and metabolic features in patients with polycystic ovary syndrome.

Authors:  M Yilmaz; E Yurtçu; H Demirci; M A Ergün; R Ersoy; A Karakoç; I Yetkin; N Cakir; G Ayvaz; M Arslan
Journal:  J Endocrinol Invest       Date:  2009-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.